Combination chemotherapy for non small cell lung cancer stage III M0-1 with cisplatin and vinblastine in a divided-dose schedule.

摘要: Twenty-nine patients with advanced non small cell lung cancer (NSCLC) were treated a combination of high-dose cisplatin and divided-dose vinblastine. In 27 evaluable 15% reached partial response 59% stable disease. Extension disease, histological type, performance status weight loss had no relationship to response. Median duration was 10.2 months median survival time 15.4 in responding compared 14 disease (p:n.s.) 4.8 progressive (p less than 0.001). Gastrointestinal, neurological side effects the development severe debilitation syndrome most troublesome toxicities this treatment. The regimen is not generally suitable for treatment NSCLC.